Disarming mutant p53 oncogenic function

Autores
Girardini Brovelli, Javier Enrique; Marotta, Carolina; del Sal, Giannino
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In the last decade intensive research has confirmed the long standing hypothesis that some p53 point mutants acquire novel activities able to cooperate with oncogenic mechanisms. Particular attention has attracted the ability of several such mutants to actively promote the development of aggressive and metastatic tumors in vivo. This knowledge opens a new dimension on rational therapy design, suggesting novel strategies based on pharmacological manipulation of those neomorphic activities. P53 point mutants have several characteristics that make them attractive targets for anti-cancer therapies. Remarkably, mutant p53 has been found predominantly in tumor cells and may act pleiotropically by interfering with a variety of cellular processes. Therefore, drugs targeting mutant p53 may selectively affect tumor cells, inactivating simultaneously several mechanisms of tumor promotion. Moreover, the high frequency of missense mutations on the p53 gene suggests that interfering with mutant p53 function may provide a valuable approach for the development of efficient therapies able to target a wide range of tumor types.
Fil: Girardini Brovelli, Javier Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Marotta, Carolina. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; Italia
Fil: del Sal, Giannino. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; Italia
Materia
Mutant P53
Cancer
Metastasis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/4827
Acceder
id CONICETDig_b67ef52998e02ef6e4a6938cb3d7a713
oai_identifier_str oai:ri.conicet.gov.ar:11336/4827
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Disarming mutant p53 oncogenic functionGirardini Brovelli, Javier EnriqueMarotta, Carolinadel Sal, GianninoMutant P53CancerMetastasishttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1In the last decade intensive research has confirmed the long standing hypothesis that some p53 point mutants acquire novel activities able to cooperate with oncogenic mechanisms. Particular attention has attracted the ability of several such mutants to actively promote the development of aggressive and metastatic tumors in vivo. This knowledge opens a new dimension on rational therapy design, suggesting novel strategies based on pharmacological manipulation of those neomorphic activities. P53 point mutants have several characteristics that make them attractive targets for anti-cancer therapies. Remarkably, mutant p53 has been found predominantly in tumor cells and may act pleiotropically by interfering with a variety of cellular processes. Therefore, drugs targeting mutant p53 may selectively affect tumor cells, inactivating simultaneously several mechanisms of tumor promotion. Moreover, the high frequency of missense mutations on the p53 gene suggests that interfering with mutant p53 function may provide a valuable approach for the development of efficient therapies able to target a wide range of tumor types.Fil: Girardini Brovelli, Javier Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Marotta, Carolina. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; ItaliaFil: del Sal, Giannino. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; ItaliaElsevier2013-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/4827Girardini Brovelli, Javier Enrique; Marotta, Carolina; del Sal, Giannino; Disarming mutant p53 oncogenic function; Elsevier; Pharmacological Research; 79; 11-2013; 75-871043-6618enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1043661813001783info:eu-repo/semantics/altIdentifier/doi/info:eu-repo/semantics/altIdentifier/doi/10.1016/j.phrs.2013.11.003info:eu-repo/semantics/altIdentifier/pmid/24246451info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:09:14Zoai:ri.conicet.gov.ar:11336/4827instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:09:14.743CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Disarming mutant p53 oncogenic function
title Disarming mutant p53 oncogenic function
spellingShingle Disarming mutant p53 oncogenic function
Girardini Brovelli, Javier Enrique
Mutant P53
Cancer
Metastasis
title_short Disarming mutant p53 oncogenic function
title_full Disarming mutant p53 oncogenic function
title_fullStr Disarming mutant p53 oncogenic function
title_full_unstemmed Disarming mutant p53 oncogenic function
title_sort Disarming mutant p53 oncogenic function
dc.creator.none.fl_str_mv Girardini Brovelli, Javier Enrique
Marotta, Carolina
del Sal, Giannino
author Girardini Brovelli, Javier Enrique
author_facet Girardini Brovelli, Javier Enrique
Marotta, Carolina
del Sal, Giannino
author_role author
author2 Marotta, Carolina
del Sal, Giannino
author2_role author
author
dc.subject.none.fl_str_mv Mutant P53
Cancer
Metastasis
topic Mutant P53
Cancer
Metastasis
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv In the last decade intensive research has confirmed the long standing hypothesis that some p53 point mutants acquire novel activities able to cooperate with oncogenic mechanisms. Particular attention has attracted the ability of several such mutants to actively promote the development of aggressive and metastatic tumors in vivo. This knowledge opens a new dimension on rational therapy design, suggesting novel strategies based on pharmacological manipulation of those neomorphic activities. P53 point mutants have several characteristics that make them attractive targets for anti-cancer therapies. Remarkably, mutant p53 has been found predominantly in tumor cells and may act pleiotropically by interfering with a variety of cellular processes. Therefore, drugs targeting mutant p53 may selectively affect tumor cells, inactivating simultaneously several mechanisms of tumor promotion. Moreover, the high frequency of missense mutations on the p53 gene suggests that interfering with mutant p53 function may provide a valuable approach for the development of efficient therapies able to target a wide range of tumor types.
Fil: Girardini Brovelli, Javier Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Marotta, Carolina. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; Italia
Fil: del Sal, Giannino. Laboratorio Nazionale CIB; Italia. Università degli Studi di Trieste. Dipartimento di Scienze della Vita; Italia
description In the last decade intensive research has confirmed the long standing hypothesis that some p53 point mutants acquire novel activities able to cooperate with oncogenic mechanisms. Particular attention has attracted the ability of several such mutants to actively promote the development of aggressive and metastatic tumors in vivo. This knowledge opens a new dimension on rational therapy design, suggesting novel strategies based on pharmacological manipulation of those neomorphic activities. P53 point mutants have several characteristics that make them attractive targets for anti-cancer therapies. Remarkably, mutant p53 has been found predominantly in tumor cells and may act pleiotropically by interfering with a variety of cellular processes. Therefore, drugs targeting mutant p53 may selectively affect tumor cells, inactivating simultaneously several mechanisms of tumor promotion. Moreover, the high frequency of missense mutations on the p53 gene suggests that interfering with mutant p53 function may provide a valuable approach for the development of efficient therapies able to target a wide range of tumor types.
publishDate 2013
dc.date.none.fl_str_mv 2013-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/4827
Girardini Brovelli, Javier Enrique; Marotta, Carolina; del Sal, Giannino; Disarming mutant p53 oncogenic function; Elsevier; Pharmacological Research; 79; 11-2013; 75-87
1043-6618
url http://hdl.handle.net/11336/4827
identifier_str_mv Girardini Brovelli, Javier Enrique; Marotta, Carolina; del Sal, Giannino; Disarming mutant p53 oncogenic function; Elsevier; Pharmacological Research; 79; 11-2013; 75-87
1043-6618
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1043661813001783
info:eu-repo/semantics/altIdentifier/doi/
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.phrs.2013.11.003
info:eu-repo/semantics/altIdentifier/pmid/24246451
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613969157816320
score 13.070432

Publicaciones similares